Contents: Research LetterHome Induction of Buprenorphine for Treatment of Opioid Use Disorder in PregnancyKelly, Jeannie C. MD, MS; Raghuraman, Nandini MD, MS; Stout, Molly J. MD, MSCI; Russell, Sharman MD; Perez, Marta MD; Nazeer, Sarah MD; El Helou, Nicole MD; Zhang, Fan MD; Carter, Ebony MD, MPHAuthor Information Division of Maternal Fetal Medicine and the Division of Clinical Research, Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, Missouri; and the Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan. Corresponding author: Jeannie C. Kelly, MD, MS, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, St. Louis, MO; email: [email protected]. Supported by grant funding provided by The PEW Charitable Trusts Community Opioid Response and Evaluation (CORE) Project, ID 00033770. Financial Disclosure Marta Perez disclosed receiving a consulting fee from Bayer Pharmaceuticals for a Physician Speaker Series (approximately five lectures and teaching sessions about IUD use). The other authors did not report any potential conflicts of interest. Each author has confirmed compliance with the journal's requirements for authorship. Peer reviews and author correspondence are available at https://links.lww.com/AOG/C416. Obstetrics & Gynecology: October 2021 - Volume 138 - Issue 4 - p 655-659 doi: 10.1097/AOG.0000000000004539 Buy SDC Metrics In Brief Buprenorphine home induction for opioid use disorder in pregnancy is associated with high rates of treatment retention and adherence. © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.